Provider supervision is especially important if symptoms are severe, persistent, or interfering with hydration, nutrition, or daily activities
Objective laboratory alcohol self-administration was evaluated at pre-treatment, i.e., prior to the first week and between weeks 8 and 9
Some patients report that these opposing effects partially cancel each other out, with phentermine providing energy during the day while tirzepatide reduces caloric intake throughout the full 24-hour cycle
Phase 3 TRIUMPH-4 (NCT05931367) reported 28.7% body weight loss at 12 mg, 26.4% at 9 mg, vs 2.1% placebo at 68 weeks
,
The options for management and eradication of Barretts have evolved over the years, and physician practice habits are changing as more options become available